News Release Details

Nautilus Biotechnology Reports Second Quarter 2023 Financial Results

Aug 02, 2023

SEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2023.

“I’m excited by the solid progress we made in Q2 against some of our foundational scientific and development goals and in the ways we continue to prepare ourselves for our commercial launch,” said Sujal Patel, CEO of Nautilus. “The type of transformational innovation that Nautilus plans to bring to market next year requires that a significant number of platform elements weave together into a seamless whole: sample preparation, affinity reagent probes, chips, flow cells, the instrument, multi-cycle assay, and software. In Q2, we demonstrated the ability to bring all of those elements together leading to routine and stable assays with higher numbers of probes and cycles. I’m especially proud of the team’s ability to execute well while maintaining exceptional fiscal discipline, preserving our balance sheet, which we now believe will fund operations through 2025 and into 2026.”

Second Quarter 2023 Financial Results

Operating expenses were $19.0 million for the second quarter of 2023, a 23% increase from $15.5 million for the three months ended June 30, 2022. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products.

Net loss was $15.8 million for the second quarter of 2023, as compared to a net loss of $14.7 million for the corresponding prior year period.

Cash, cash equivalents, and investments were $286.7 million as of June 30, 2023.

Webcast and Conference Call Information

Nautilus will host a conference call to discuss the second quarter 2023 financial results, business developments and outlook before market open on Wednesday, August 2, 2023 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at:

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the timing of the launch of Nautilus’ product platform and full commercial availability, the functionality and performance of Nautilus’ product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended June 30, 2023 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Disclosure Information

Nautilus uses filings with the Securities and Exchange Commission, its website (, press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

Media Contact

Investor Contact

Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
As of June 30, 2023 and December 31, 2022 (Unaudited)

(in thousands, except share and per share amounts)June 30,
 December 31,
Current assets:   
Cash and cash equivalents        $72,139  $114,523 
Short-term investments         91,156   69,948 
Prepaid expenses and other current assets         3,408   2,738 
Total current assets         166,703   187,209 
Property and equipment, net         4,178   3,700 
Operating lease right-of-use assets         34,684   28,866 
Long-term investments          123,433   129,169 
Other long-term assets         1,769   1,108 
Total assets        $330,767  $350,052 
Liabilities and Stockholders’ Equity   
Current liabilities:   
Accounts payable        $1,222  $1,272 
Accrued expenses and other liabilities         3,411   3,528 
Current portion of operating lease liability         3,257   1,991 
Total current liabilities         7,890   6,791 
Operating lease liability, net of current portion         33,204   28,337 
Total liabilities         41,094   35,128 
Stockholders’ equity:   
Preferred stock             
Common stock         12   12 
Additional paid-in capital         461,387   455,330 
Accumulated other comprehensive loss         (2,389)  (1,854)
Accumulated deficit         (169,337)  (138,564)
Total stockholders’ equity         289,673   314,924 
Total liabilities and stockholders’ equity        $330,767  $350,052 


Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
Three and Six Months Ended June 30, 2023 and 2022 (Unaudited)

 Three Months Ended June 30, Six Months Ended June 30,
(in thousands, except share and per share amounts) 2023   2022   2023   2022 
Operating expenses       
Research and development        $11,912  $8,856  $22,789  $18,514 
General and administrative         7,104   6,616   14,287   12,980 
Total operating expenses         19,016   15,472   37,076   31,494 
Other income (expense), net         3,208   783   6,303   1,042 
Net loss        $(15,808) $(14,689) $(30,773) $(30,452)
Net loss per share attributable to common stockholders, basic and diluted        $(0.13) $(0.12) $(0.25) $(0.24)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted         124,603,181   124,494,036   124,601,762   124,456,518 


Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
Six Months Ended June 30, 2023 and 2022 (Unaudited)

 Six Months Ended June 30,
(in thousands) 2023   2022 
Cash flows from operating activities   
Net loss        $(30,773) $(30,452)
Adjustments to reconcile net loss to net cash used in operating activities           
Depreciation         826   562 
Stock-based compensation         5,958   4,677 
Amortization (accretion) of premium (discount) on securities, net         (1,412)  (147)
Amortization of operating lease right-of-use assets 1,806   1,073 
Changes in operating assets and liabilities:   
Prepaid expenses and other assets         (787)  (503)
Accounts payable         (199)  (643)
Accrued expenses and other liabilities         (117)  (11)
Operating lease liabilities         (1,375)  (420)
Net cash used in operating activities         (26,073)  (25,864)
Cash flows from investing activities   
Proceeds from maturities of securities          32,249   105,575 
Purchases of securities          (46,844)  (54,185)
Purchases of property and equipment         (1,155)  (1,132)
Net cash (used in) provided by investing activities         (15,750)  50,258 
Cash flows from financing activities   
Proceeds from exercise of stock options         7   188 
Proceeds from issuance of common stock under employee stock purchase plan         92   153 
Net cash provided by financing activities         99   341 
Net (decrease) increase in cash, cash equivalents and restricted cash         (41,724)  24,735 
Cash, cash equivalents and restricted cash at beginning of period         115,477   186,461 
Cash, cash equivalents and restricted cash at end of period        $73,753  $211,196